LIMD1 Is Induced by and Required for LMP1 Signaling, and Protects EBV-transformed Cells From DNA Damage-Induced Cell Death

Autor: Wang, Ling, Howell, Mary E. A., McPeak, Brooke, Riggs, Katrina, Kohne, Carissa, Yohanon, Jether Uel, Foxler, Daniel E., Sharp, Tyson V., Moorman, Jonathon P., Yao, Zhi Q., Ning, Shunbin

Publikováno v: ETSU Faculty Works.

LIMD1 (LIM domain-containing protein 1) is considered as a tumor suppressor, being deregulated in many cancers to include hematological malignancies; however, very little is known about the underlying mechanisms of its deregulation and its roles in c

Externí odkaz: https://dc.etsu.edu/etsu-works/6525
https://dc.etsu.edu/context/etsu-works/article/7776/viewcontent/LIMD1_is_induced_by_and_required_for_LMP1_signaling.pdf

LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death.

Autor: Wang L; Center of Excellence for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA., Howell MEA; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA., McPeak B; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA., Riggs K; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA., Kohne C; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA., Yohanon JU; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA., Foxler DE; Centre for Molecular Oncology, Barts Cancer Institute, University of London, London EC1M 6BQ, UK., Sharp TV; Centre for Molecular Oncology, Barts Cancer Institute, University of London, London EC1M 6BQ, UK., Moorman JP; Center of Excellence for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.; Hepatitis (HCV/HIV) Program, James H Quillen VA Medical Center, Johnson City 37614, TN, USA., Yao ZQ; Center of Excellence for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.; Hepatitis (HCV/HIV) Program, James H Quillen VA Medical Center, Johnson City 37614, TN, USA., Ning S; Center of Excellence for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.; Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA.

Publikováno v: Oncotarget [Oncotarget] 2017 Dec 26; Vol. 9 (5), pp. 6282-6297. Date of Electronic Publication: 2017 Dec 26 (Print Publication: 2018).